XL092 Clinical Trials
3 recruitingDrug
Phase 22Phase 11
Showing 1–3 of 3 trials
Recruiting
Phase 2
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Metastatic Renal Cell CarcinomaAdvanced Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Karie Runcie70 enrolled2 locationsNCT06863311
Recruiting
Phase 2
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
University of Utah32 enrolled1 locationNCT06568562
Recruiting
Phase 1
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Thyroid CancerBRAF Mutation-Related TumorsAnaplastic Thyroid Cancer
UNC Lineberger Comprehensive Cancer Center12 enrolled2 locationsNCT06902376